Although RFAs includig rhein, diacerein, emodin, aloe emodin, and 1,8-dihydroxyanthraquinone were screened out as NLRP3 inflammasome blockers to treat NAFLD, while many questions still exit in this paper and we will try to solve these problems in our next researches: (1) there is no clinical trial to provide more evidence for the role of RFAs in treating NAFLD; (2) the deeper mechanism that RFAs inhibited NLRP3 inflammasome are still unkown; (3) How to choose the clinical application of these effective RFAs or rhubarb or prescription containing rhubarb in clinical treatment of NAFLD? Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.